GlassScriptPhysician profile
Annmarie Pirone
NPI 1528706942
$1,276.82
in general payments reported to CMS, 2019-2025
14 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $308 · 2024: $494 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $285.84 | 2023-2025 | Mounjaro, Jardiance, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $217.62 | 2024-2025 | |
| Exact Sciences Corporation | $213.59 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $185.18 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $126.00 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.26 | 2024 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $50.49 | 2023-2024 | |
| Medtronic, INC. | $37.47 | 2024 | Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $28.77 | 2024 | Shingrix |
| Abbvie INC. | $17.63 | 2024 | |
| Amgen INC. | $16.74 | 2024 | Otezla, Repatha |
| Dynavax Technologies Corporation | $16.57 | 2023 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.19 | 2024 | Trulance, Xifaxan |
| Bausch Health US, LLC | $13.47 | 2025 | Wellbutrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annmarie Pirone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.